JMP Securities Sticks to Their Buy Rating for KalVista Pharmaceuticals (KALV)
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) today and set a price ...
JMP Securities maintains Enanta stock with $21 target
JMP Securities reiterated a Market Outperform rating on Enanta Pharmaceuticals (NASDAQ:ENTA) shares with a consistent price target of $21.00. The firm's analysis highlighted the company's solid ...
JMP Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)
JMP Securities analyst Jason Butler maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $78.00.
JMP Securities Raises Axon Enterprise, Inc. (AXON) Price Target to $725 on AI & Defense Demand
As the US stock markets were catching up with the tech disruption led by cheap Chinese AI models, US President Donald Trump’s ...
JMP maintains Apollo stock Market Perform rating
JMP Securities maintained its Market Perform rating on Apollo Global Management (NYSE:APO) shares without setting a new price ...
KBC Group NV Boosts Stake in Sabra Health Care REIT, Inc. (NASDAQ:SBRA)
KBC Group NV increased its holdings in Sabra Health Care REIT, Inc. (NASDAQ:SBRA – Free Report) by 66.2% in the fourth ...